Arrowhead Pharmaceuticals (ARWR) Change in Receivables (2011 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 16 years of Change in Receivables data on file, last reported at -$203.2 million in Q1 2026.

• Quarterly Change in Receivables fell 150407.41% year-over-year to -$203.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.5 million (up 2583.42% YoY) and the FY2025 annual result came in at $57.0 million, changed N/A from the prior year.
• Change in Receivables fell to -$203.2 million in Q1 2026, from $212.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $212.0 million in Q4 2025 to a low of -$203.2 million in Q1 2026.
• A 5-year average of $5.1 million and a median of $1.2 million in 2022 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2025 — Change in Receivables jumped 8381.84% — and 2026, when it slumped 150407.41%.
• Tracing ARWR's Change in Receivables over 5 years: stood at $38.2 million in 2022, then tumbled by 103.27% to -$1.2 million in 2023, then jumped by 300.64% to $2.5 million in 2024, then jumped by 8381.84% to $212.0 million in 2025, then slumped by 195.82% to -$203.2 million in 2026.
• The last three Change in Receivables figures came in at -$203.2 million (Q1 2026), $212.0 million (Q4 2025), and $47.1 million (Q3 2025), per Business Quant data.